Tempus AI, Inc. (NASDAQ:TEM) CFO Sells $2,616,447.40 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 31,780 shares of Tempus AI stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the sale, the chief financial officer now owns 189,320 shares in the company, valued at $15,586,715.60. This represents a 14.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James William Rogers also recently made the following trade(s):

• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total transaction of $588,669.84.
• On Monday, December 16th, James William Rogers sold 1,468 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $59,057.64.
• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The stock was sold at an average price of $42.30, for a total transaction of $3,511,957.50.

Tempus AI Stock Down 10.5 %

Shares of Tempus AI stock traded down $8.99 during trading on Thursday, reaching $76.72. The company’s stock had a trading volume of 20,409,815 shares, compared to its average volume of 14,385,644. The stock has a 50-day moving average price of $49.75 and a two-hundred day moving average price of $51.44. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45.

Analyst Ratings Changes

Several brokerages have recently commented on TEM. Piper Sandler restated a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Loop Capital reduced their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, TD Cowen restated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $58.55.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Tempus AI during the 4th quarter worth about $108,000. Voloridge Investment Management LLC bought a new stake in Tempus AI during the 4th quarter worth about $11,826,000. Two Sigma Advisers LP bought a new stake in Tempus AI during the 4th quarter worth about $625,000. ProShare Advisors LLC bought a new stake in Tempus AI during the 4th quarter worth about $244,000. Finally, Lazard Asset Management LLC bought a new stake in Tempus AI during the 4th quarter worth about $1,034,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.